Wrist wearable uses pulses to relieve chronic motion sickness

Chronic motion sickness patients could be helped by the Reliefband, a wearable that uses pulses to block signals entering the part of the brain related to nausea. 

More than 30 million people suffer from chronic motion sickness and experience nausea or vertigo when traveling. The U.S. Food and Drug Administration-cleared Reliefband wearable uses the body’s own neural pathways to control nausea. The wearable delivers pulses to the media nerve at the pressure point at the underside of the wrist. These pulses send signals to the nausea center of the brain to alleviate symptoms for patients.

“Since 2014, the company has demonstrated the viability of our technology in the over-the-counter healthcare market by significantly growing unit and dollar sales,” according to Nick Spring, president and CEO of Reliefband Technologies. “Reliefband Technologies has primarily focused on direct-to-consumer online distribution, and recently, due to uplifting demand has selectively increased distribution in specialty retail environments. Given the rapid increase in wearable technology and consumers desiring to manage their health without medications, new approaches like ours are on the forefront of helping those in need.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup